The role of fungal sensitisation in clinical presentation in patients with chronic obstructive pulmonary disease

Abstract

Atopic patients with chronic obstructive pulmonary disease (COPD) demonstrate more severe symptoms than their non‐atopic counterparts. Also, Aspergillus hypersensitivity is known in COPD. However, allergic sensitisation to non‐Aspergillus fungi has never been studied in COPD patients. To evaluate the prevalence of fungal sensitisation and its impact on the clinical presentation and outcome of COPD patients. Sensitisation to 17 fungi was studied in 55 COPD patients through skin prick tests, fungus‐specific IgE, precipitating antibodies, total IgE and eosinophil counts. The clinical symptoms of patients were monitored thorough a patient‐administered questionnaire. Overall, 5.4% (n = 3) of COPD patients were fungus sensitive. The sensitisation was noted to Alternaria alternata and Schizophyllum commune in two patients each, whereas another was sensitive to A. tamarii, Rhizopus spp. and Aspergillus fumigatus. Eosinophils were higher in fungus‐sensitised patients (P = 0.001 vs. 0.003). No differences were noted in the clinical presentation of patients sensitised to fungi compared to those not sensitised to fungi or non‐atopic. Although low, fungal sensitisation occurs in COPD but it is not limited to Aspergilli alone. Fungus‐sensitised patients exhibit greater eosinophilia, implying more severe inflammation. Thus, such patients should be followed up regularly to recognise clinical worsening or development of ABPM.